Systemic mastocytosis · 8 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Midostaurin monotherapy Variant #01 | — | R 76 418 | 28d | — | — | — | — | — |
Cladribine monotherapy Variant #01 | — | R 59 905 | 5d | — | — | — | — | — |
Nilotinib monotherapy Variant #01 | — | R 27 206 | 28d | — | — | — | — | — |
Imatinib monotherapy Variant #17 | — | R 27 014 | 30d | ~20.0 mo | ~53.0 mo | ~21 | ~R 567 284 PFS proxy · indirect | 8 |
Dasatinib monotherapy Variant #01 | — | R 12 899 | 28d | — | — | — | — | — |
Placebo Partial | — | — | — | ~4.2 mo | ~8.0 mo | — | — | 145 |
Avapritinib monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | — |
Interferon alfa-2b monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | 1 |
8 of 8 regimens shown